New research at the Lewis Katz School of Medicine at Temple University shows that in experiments carried out in mice, drugs known as carbonic anhydrase inhibitors (CAIs), already FDA-approved for other conditions, promote the clearance of amyloid beta from blood vessels and glial cells, which control brain inflammatory processes. In doing so, CAIs not only reduce inflammation and restore cell function but also prevent cognitive impairment. The study took place in the lab of Silvia Fossati, PhD, Associate Professor of Neural Sciences and Cardiovascular Sciences at the Katz School of Medicine, and is the first to test the FDA-approved CAIs acetazolamide and methazolamide in animals with cerebrovascular alterations mimicking those of cerebral amyloid angiopathy and Alzheimer’s disease in humans. The results appeared online in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Multiple outlets, including Medical Xpress, Scienmag and Neuroscience News, highlighted the news.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH